Saad A. Khan

Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study

Barbara Burtness, Kevin J. Harrington, Richard Greil et al. · The Lancet · 2019 · 3.2K citations · Full text

Medicine, Oncology, Cancer Pharmacology +11

Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial

Vivek Subbiah, Jürgen Wolf, Bhavana Konda et al. · The Lancet Oncology · 2022 · 420 citations · Full text

Medicine, Oncology, Endocrine Oncology +13

Immune dysregulation in cancer patients developing immune-related adverse events

Shaheen Khan, Saad A. Khan, Xin Luo et al. · British Journal of Cancer · 2018 · 186 citations · Full text

Life Sciences, Immunology, Oncology +14

Prevalence of Autoimmune Disease Among Patients With Lung Cancer

Saad A. Khan, Sandi L. Pruitt, Lei Xuan et al. · JAMA Oncology · 2016 · 177 citations · Full text

Life Sciences, Immunology, Oncology +12

Phase III KEYNOTE-789 Study of Pemetrexed and Platinum With or Without Pembrolizumab for Tyrosine Kinase Inhibitor‒Resistant, <i>EGFR</i> –Mutant, Metastatic Nonsquamous Non–Small Cell Lung Cancer

James Chih‐Hsin Yang, Dae Ho Lee, Jong‐Seok Lee et al. · Journal of Clinical Oncology · 2024 · 142 citations · Full text

Medicine, Oncology, Pharmacology +14